Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue declined despite higher sales of PGA resin processed products, due to the termination of sales of heat-shrinkable multilayer film in the first half of the previous fiscal year and lower sales of polyvinylidene fluoride resin. Operating profit deteriorated due to impairment losses on fixed assets resulting from the delayed recovery in demand amid the stagnation of the EV market, as well as impairment losses on manufacturing equipment for drugs used to treat chronic renal failure resulting from the contraction of the spherical adsorbent carbon market and cuts in drug prices.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥161,688 million (YoY -0.2%) |
| Operating profit | ¥-18,592 million |
| Ordinary income | ¥-18,310 million |
| Profit attributable to owners of the parent | ¥-10,693 million |
| Net income per share | △¥267.14 |
| Operating Margin | -11.5 |
| Equity ratio | End of the current fiscal period 48.8 / End of previous period 60.6 |
| Total assets | ¥338,444 million |
| Net assets | ¥167,179 million |
| Cash flows from operating activities | ¥28,009 million |
| Cash flows from investing activities | ¥-13,723 million |
| Cash flows from financing activities | ¥-7,959 million |
| Cash and cash equivalents at end of period | ¥29,726 million |
| Full-year earnings forecast | Net Sales ¥172,000 million (YoY +6.4%) / Operating profit ¥11,000 million / Ordinary income ¥10,500 million / Net income ¥7,500 million |
| Annual Dividend Forecast | ¥214 → ¥216 |
| Payout ratio | 110.1 |
| Shareholder Return Policy | Dividend targeting a DOE (dividend on equity) ratio of 5% |
| Segment revenue | Functional Products Business ¥61,279 million (YoY +6.8%), Chemical Products Business ¥29,487 million (YoY -3.9%), Resin Products Business ¥36,724 million (YoY -9.4%), Construction-Related Business ¥16,013 million (YoY +7.9%), Other Related Businesses ¥18,183 million (YoY -2.2%) |
| Segment profit | Functional Products Business ¥2,134 million, Chemical Products Business ¥1,350 million (YoY +128.0%), Resin Products Business ¥6,913 million (YoY -2.6%), Construction-Related Business ¥1,533 million (YoY +10.1%), Other Related Businesses ¥2,592 million (YoY -11.0%) |
| Depreciation and amortization | ¥12,339 million |
| Impairment loss | ¥36,500 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | At a meeting of the Board of Directors held on 12 May 2026, the Company resolved to cancel 9,700,000 treasury shares on 30 June 2026. The total number of issued shares after the cancellation will be 40,242,221. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 49,942,221 |
| Treasury Shares at Period-End | 11,723,323 |
| Factors Behind Changes in Business Performance | Revenue declined despite higher sales of PGA resin processed products, due to the termination of sales of heat-shrinkable multilayer film in the first half of the previous fiscal year and lower sales of polyvinylidene fluoride resin. Operating profit deteriorated due to impairment losses on fixed assets resulting from the delayed recovery in demand amid the stagnation of the EV market, as well as impairment losses on manufacturing equipment for drugs used to treat chronic renal failure resulting from the contraction of the spherical adsorbent carbon market and cuts in drug prices. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As the stagnation in the EV market continued, the recovery in demand for polyvinylidene fluoride resin was expected to take longer than anticipated. The Company therefore revised its future earnings projections and recognized an impairment loss on fixed assets related to this business. It also recognized an impairment loss on manufacturing equipment for drugs used to treat chronic renal failure, due to the contraction of the spherical adsorbent carbon market following the emergence of new therapies and annual cuts in drug prices.